Objective. To evaluate the pharmacokinetics, tolerance, safety, immunologic effects, and antiviral activity of combination therapy with d4T, ddI, and indinavir in HIV-infected children.

Methods. Twelve children (median age, 8.8 years; range, 4.2 to 13.5 years) with HIV infection (median CD4+ lymphocyte count at baseline, 48 cells/uL; range, eight to 878 cells/uL) and a history of prior nucleoside antiretroviral therapy (zidovudine, ddI, and/or d4T; median duration, >4 years) were treated orally with d4T (1 mg/kg/dose every 12 hours), ddI (90 mg/sq. meter/dose every 12 hours), and indinavir (500 mg/sq. meter/dose every six or eight hours) for at least 12 weeks each as of 12/96. Children were assessed at baseline, and every four weeks thereafter.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD